




ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



ORIGINAL ARTICLE

[Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyr[®]) Still be Part of the Baseline Series?



C.P. Hernández Fernández ^{a,*}, L. Borrego ^b, A.M. Giménez Arnau ^c, T. Sanz Sánchez ^d, J.M. Carrascosa Carrillo ^e, V. Zaragoza Ninet ^f, E. Serra Baldrich ^g, F.J. Miquel Miquel ^h, J.F. Silvestre Salvador ⁱ, S. Córdoba Guijarro ^j, A. Sánchez Giló ^k, P. Mercader García ^l, F. Navarro Triviño ^m, F. Tous Romero ⁿ, M. Rodríguez Serna ^o, G. Melé Ninot ^p, I. Ruiz González ^q, E. Gómez de la Fuente ^r, M.A. Pastor Nieto ^s, P. Sánchez-Pedreño Guillén ^t, J. Sánchez Pérez ^u, J.J. Pereyra Rodríguez ^v, M.E. Gatica Ortega ^w, R. González Pérez ^x, I. García Doval ^y, M.A. Gallego Descalzo ^y

^a Servicio de Dermatología, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain

^b Servicio de Dermatología, Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain

^c Servicio de Dermatología, Hospital del Mar Research Institute, Barcelona, Spain

^d Servicio de Dermatología, Hospital Universitario Infanta Sofía, Madrid, Spain

^e Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

^f Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain

^g Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^h Servicio de Dermatología, Hospital Universitario Arnau de Vilanova, Valencia, Spain

ⁱ Servicio de Dermatología, Hospital General Universitario Doctor Balmis, ISABIAL, Alicante, Spain

^j Servicio de Dermatología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain

^k Servicio de Dermatología, Hospital Universitario Rey Juan Carlos, Madrid, Spain

^l Servicio de Dermatología, Hospital General Universitario Morales Meseguer, Murcia, Spain

^m Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, Spain

ⁿ Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain

^o Servicio de Dermatología, Hospital Universitario La Fe, Valencia, Spain

^p Servicio de Dermatología, Hospital Universitari Sagrat Cor, Grupo Quirónsalud, Barcelona, Spain

^q Servicio de Dermatología, Complejo Asistencial Universitario de León, León, Spain

^r Servicio de Dermatología, Hospital Universitario Ramón y Cajal, Madrid, Spain

^s Servicio de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

^t Servicio de Dermatología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

Available online 9 October 2025

DOI of original article:

<https://doi.org/10.1016/j.ad.2024.10.063>

* Corresponding author.

E-mail address: cphefer@gobiernodecanarias.org (C.P. Hernández Fernández).

<https://doi.org/10.1016/j.ad.2025.10.016>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

^u Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain^v Servicio de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain^w Servicio de Dermatología, Complejo Hospitalario Universitario de Toledo, Toledo, Spain^x Servicio de Dermatología, Hospital Universitario Araba, Universidad del País Vasco, Vitoria, Araba, Spain^y Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, Spain

Received 9 May 2024; accepted 6 October 2024

Available online 9 October 2025

KEYWORDSContact dermatitis;
Hydroxyisohexyl
3-cyclohexene
carboxaldehyde;
Lyrál®;
Patch tests;
Spain;
Baseline series**Abstract**

Background and objectives: Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyrál®, is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021.

We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish baseline series.

Material and method: We analyzed all consecutive patients simultaneously patch-tested with HICC and FM II within the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 to December 31st, 2023.

Results: A total of 96 (0.8%) out of 12,029 patients analyzed yielded positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II was patched.

Conclusions: Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish baseline series and support its exclusion from the European baseline series.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVEDermatitis de
contacto;
Hidroxiisohexil
3-ciclohexeno
carboxaldehído;
Lyrál®;
Pruebas epicutáneas;
España;
Batería estándar**¿Debe continuar el hidroxiiisohexil 3-ciclohexeno carboxaldehído (Lyrál®) en las baterías estándar de las pruebas epicutáneas?****Resumen**

Antecedentes y objetivo: El hidroxiiisohexil 3-ciclohexeno carboxaldehído (HICC), o Lyrál®, es un marcador de fragancias que forma parte de la mezcla de fragancias II (MF II), y aún se parchea como alérgeno independiente dentro de la batería estándar europea y otras baterías nacionales, pese a que la Comisión Europea prohibió su uso en cosméticos en el año 2021. Nuestro objetivo es estudiar la prevalencia de sensibilización al HICC en España y la positividad simultánea con la MF II, para determinar si debería formar parte de la batería estándar española.

Material y método: Analizamos todos los pacientes consecutivos del Registro Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (REIDAC) parcheados simultáneamente con HICC y MF II, desde el 01 de junio de 2018 al 31 de diciembre de 2023.

Resultados: De 12.029 pacientes analizados, 96 (0,8%) fueron positivos al HICC y 396 (3,3%) a la MF II, con una relevancia presente del 53 y 64%, respectivamente. Setenta y dos de los 96 (75%) pacientes sensibilizados al HICC serían detectados si solamente se parchease la MF II.

Conclusiones: La prevalencia de sensibilización al HICC en España es baja y ha disminuido en los últimos años. El HICC es una fragancia prohibida en cosméticos y la MF II detecta a 3 de cada 4 pacientes sensibilizados. Nuestros resultados sugieren que el HICC debe permanecer fuera de la batería estándar española y apoyan su exclusión de la batería estándar europea.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

Introduction

Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) (CAS no. [31906-04-4]) or Lyrall® is a synthetic fragrance that is patch-tested independently (5% pet.) or as part of the fragrance mix II (FM II) within the European baseline series of patch tests,¹ and also as part of fragrance series in patients with suspected allergic contact dermatitis (ACD). FM II (14% pet.) is composed of a total of 6 fragrances: hexyl cinnamic aldehyde (5% pet.), HICC (2.5% pet.), coumarin (2.5% pet.), farnesol (2.5% pet.), citral (1% pet.), and citronellol (0.5% pet.). Because of their importance, HICC and FM II were added as allergens to the European baseline series in 2008.² In Spain, both have been included as allergens in the Spanish baseline series since 2012,³ although HICC was removed from the Spanish baseline series in 2022, becoming part of the Spanish extended series.⁴

The most recent European studies indicate a decrease in the prevalence of sensitization to HICC in recent years, currently around 1%.^{5–9} In most studies, the percentage of HICC-positive patients who would be missed if only FM II were patch-tested within a baseline series is approximately 15–20%. For this reason, some authors have recommended eliminating HICC from European and national baseline series.^{8–13}

The primary endpoint of this study is to evaluate the frequency of sensitization to HICC in Spain during the period 2018–2023 and the simultaneous positivity to FM II to determine whether HICC should remain part of the Spanish baseline series. Secondary endpoints include assessing the clinical relevance of sensitization and the clinical–epidemiological characteristics of the sensitized population.

Materials and methods

The Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy (REIDAC) prospectively collects clinical information from all patients studied with patch tests in participating hospitals in Spain.¹⁴ We conducted an observational, cross-sectional study including unselected patients from REIDAC, consecutively and simultaneously patch-tested with HICC (5% pet.) and FM II (14% pet., of which 2.5% is HICC), as part of the Spanish baseline and the 2022 Spanish extended series, from June 1st, 2018 to December 31st, 2023.

Allergens were obtained from Chemotechnique Diagnostics® (Vellinge, Sweden) and allergEAZE® (Smart-Practice, Calgary, Canada), depending on center availability. Patch tests were performed according to the clinical practice guidelines of the European Society of Contact Dermatitis (ESCD).¹⁵ Reactions scored as (+), (++) or (+++) were considered positive. Relevance (current, past, irritant, active sensitization, cross-reactivity, unknown) was determined based on clinical history. Data collected included MOAHLFA index variables (Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40 years), the patient's main occupation, and the main site of dermatitis.

Continuous variables (age) were expressed as arithmetic mean (standard deviation), and categorical variables as

Table 1 Frequency of positives and relevance to hydroxyisohexyl 3-cyclohexene carboxaldehyde and Fragrance Mix II.

	Reactions Positive					Relevance							
	All (% ^a)	+ (% ^b)	++ (% ^b)	+++ (% ^b)	Irritant (% ^a)	Doubtful ?+ (% ^a)	Current (%)	Past (%)	Irritant (%)	Active sensitization (%)	Cross-reactivity (%)	Unknown (%)	
HICC	96 (0.8)	40 (41)	43 (45)	13 (14)	1 (0.01)	14 (0.1)	51 (53.1)	13 (13.5)	1 (1.0)	0 (0)	0 (0)	31 (32.3)	
FM II	396 (3.3)	176 (44)	172 (43)	48 (12)	1 (0.01)	52 (0.4)	255 (64.4)	27 (6.8)	11 (2.8)	2 (0.5)	1 (0.3)	100 (25.3)	

HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; FM II: Fragrance Mix II.

^a Percentage over the total patch-tested ($n = 12,029$).

^b Percentage over the total positives.




Figure 1 Annual variation in positivity frequency to hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrall) and fragrance mix II (FM II). Solid lines illustrate annual variation for all positives (Lyrall: blue line; FM II: brown line) and positives with current relevance (Lyrall: green line; FM II: orange line). Dashed lines illustrate trend variation for all positives (Lyrall: green line; FM II: red line) and positives with current relevance (Lyrall: blue line; FM II: yellow line).

counts (proportions). Fisher's exact test was used as univariate analysis to study the association between MOAHLFA variables and positivity to HICC and FM II, expressed as odds ratios (OR) with 95% confidence intervals (95%CI). Results were considered significant when $p \leq 0.05$. Statistical analyses were performed using Stata® 16 (StataCorp. 2019. Stata® Statistical Software: Release 16. College Station, TX: StataCorp LLC, RRID: SCR.012763).

Results

Sensitization and relevance

A total of 12,029 unselected patients were studied (Table 1). The overall rate of sensitization to HICC was 0.8% (96/12,029). Of these, 53.1% (51/96) were of current relevance. The overall frequency of sensitization to FM II was 3.3% (396/12,029), of which 64.4% (255/396) were of current relevance. The proportion of weak (+), moderate (++), and strong (+++) reactions was similar in both groups.

The annual frequency of sensitization to HICC ranged between 0.56% and 1.14%, with no significant variation ($p=0.059$) (Fig. 1). Considering only cases of current relevance, the frequency ranged between 0.15% and 0.50%, with a significant decreasing trend over time ($p=0.026$). The annual frequency of sensitization to FM II went from 2.26% to 4.02%, without significant variation ($p=0.081$). Considering only cases of current relevance, the frequency ranged between 1.53% and 2.56%, with no significant variation ($p=0.170$).

Simultaneous positivity to HICC and FM II

Of HICC-positive patients, 75% (72/96) also tested positive to FM II (Table 2, Fig. 2). Considering only the subgroup with

Table 2 Frequency of negatives and simultaneous positives to hydroxyisohexyl 3-cyclohexene carboxaldehyde and Fragrance Mix II.

	FM II		Total
	Negatives	Positives	
HICC			
Negatives (% ^a)	11,609 (97.3)	324 (2.7)	11,933
Positives (% ^b)	24 (25)	72 (75)	96
Total	11,633	396	12,029

HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; FM II: Fragrance Mix II.

^a Percentage over the total HICC-negative ($n=11,933$).

^b Percentage over the total HICC-positive ($n=96$).

current relevance, 74.5% (38/51) of HICC-positive patients also tested positive to FM II.

Of FM II-positive patients, 18.2% (72/396) also tested positive to HICC. Considering only the subgroup with current relevance, 14.9% (38/255) of FM II-positive patients also tested positive to HICC.

Factors associated with positivity to HICC and FM II

The MOAHLFA index of HICC-positive patients was similar to that of FM II-positive patients (Tables 3 and 4). Sensitization to HICC was not significantly associated with any MOAHLFA variable (Table 3). FM II positivity was significantly associated with higher frequency of age > 40 years ($p=0.002$) and lower frequency of facial involvement ($p=0.001$). Considering only the subgroup of patients with current relevance, FM II positivity was significantly associated with higher fre-

Table 3 Population characteristics and odds ratios for positivity to hydroxyisohexyl 3-cyclohexene carboxaldehyde.

	HICC, all patch-tested (%)	HICC, negatives (%)	HICC, positives (%)	OR (95%CI)	HICC, positives with current relevance (%)	OR (95%CI)
<i>Total</i>	12,029 (100)	11,933 (99.2 ^a)	96 (0.8 ^a)		51 (0.4 ^a)	
<i>MOAHLFA</i>						
Sex (M)	3635 (30)	3610 (30)	25 (26)	0.8 (0.5–1.3)	15 (29)	1.0 (0.5–1.8)
Occupational (O)	1069 (9)	1066 (9)	3 (3)	0.3 (0.1–1.1)	1 (2)	0.2 (0.03–1.5)
Atopic dermatitis (A)	2228 (19)	2207 (19)	21 (22)	1.2 (0.75–2)	12 (24)	1.3 (0.7–2.6)
Hand location (H)	3721 (31)	3698 (31)	23 (24)	0.7 (0.4–1.1)	11 (22)	0.6 (0.3–1.2)
Leg location (L)	609 (5)	607 (5)	2 (2)	0.4 (0.1–1.6)	2 (4)	0.8 (0.2–3.1)
Face location (F)	2869 (24)	2849 (24)	20 (21)	0.8 (0.5–1.4)	11 (22)	0.9 (0.45–1.7)
Age > 40 years (A)	8124 (68)	8057 (68)	67 (70)	1.1 (0.7–1.7)	30 (59)	0.7 (0.4–1.2)
Mean age (SD)	48.4 (18.3)	48.4 (18.0)	48.4 (18.6)	1.0 (0.99–1.01)	47.2 (15.4)	1.0 (0.98–1.01)
<i>Main occupation</i>						
Administrative	1341 (11)	1314 (11)	27 (28)		14 (27)	
Service sector	607 (5)	595 (5)	12 (13)		6 (12)	
Retired	2091 (17)	2079 (17)	12 (13)		5 (10)	
Homemaker	1151 (10)	1145 (10)	6 (6)		4 (8)	
Health care	897 (7)	892 (7)	5 (5)		4 (8)	
Other/unknown	5942 (49)	5908 (50)	34 (35)		18 (35)	
<i>Main site of dermatitis</i>						
Hands	3721 (31)	3698 (31)	23 (24)		11 (22)	
Legs	609 (5)	607 (5)	2 (2)		2 (4)	
Face	2869 (24)	2849 (24)	20 (21)		11 (22)	
Trunk	1868 (16)	1847 (16)	21 (22)		14 (27)	
Neck	350 (3)	343 (3)	7 (7)		5 (10)	
Other/unknown	2612 (22)	2589 (22)	23 (24)		8 (16)	

SD: standard deviation; HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; 95%CI: 95% confidence interval; MOAHLFA: Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40; OR: odds ratio.

^a Percentage over all patch-tested ($n = 12,029$).

Table 4 Population characteristics and odds ratios for positivity to Fragrance Mix II.

	FM II, all patch-tested (%)	FM II, negatives (%)	FM II, positives (%)	OR (95%CI)	FM II, positives with current relevance (%)	OR (95%CI)
<i>Total</i>	12,029 (100)	11,633 (96.7 ^a)	396 (3.3 ^a)		255 (2.1 ^a)	
<i>MOAHLFA</i>						
Sex (M)	3635 (30)	3506 (30)	129 (33)	1.1 (0.9–1.4)	87 (34)	1.2 (0.9–1.6)
Occupational (O)	1069 (9)	1032 (9)	37 (10)	1.1 (0.75–1.5)	22 (9)	1.0 (0.6–1.5)
Atopic dermatitis (A)	2228 (19)	2160 (19)	68 (17)	0.9 (0.7–1.2)	42 (17)	0.9 (0.6–1.2)
Hand location (H)	3721 (31)	3597 (31)	124 (31)	1.0 (0.8–1.3)	68 (27)	0.8 (0.6–1.1)
Leg location (L)	609 (5)	585 (5)	24 (6)	1.2 (0.8–1.85)	18 (7)	1.4 (0.9–2.3)
Face location (F)	2869 (24)	2804 (24)	65 (16)	0.6 (0.5–0.8)	46 (18)	0.7 (0.5–0.96)
Age > 40 years (A)	8124 (68)	7829 (68)	295 (75)	1.4 (1.1–1.8)	189 (74)	1.4 (1.04–1.85)
Mean age (SD)	48.4 (18.3)	48.3 (18.0)	51.1 (17.7)	1.0 (1.00–1.01)	50.9 (18.8)	1.0 (1.00–1.01)
<i>Main occupation</i>						
Administrative	1341 (11)	1283 (11)	58 (15)		39 (15)	
Service sector	607 (5)	586 (5)	21 (5)		12 (5)	
Retired	2091 (17)	2005 (17)	86 (22)		52 (20)	
Homemaker	1151 (10)	1128 (10)	23 (6)		17 (7)	
Health care	897 (7)	865 (7)	32 (8)		17 (7)	
Other/unknown	5906 (49)	5766 (50)	140 (35)		137 (54)	
<i>Main site of dermatitis</i>						
Hands	3721 (31)	3597 (31)	124 (31)		68 (27)	
Legs	609 (5)	585 (5)	24 (6)		18 (7)	
Face	2869 (24)	2804 (24)	65 (16)		46 (18)	
Trunk	1868 (16)	1785 (15)	83 (21)		61 (24)	
Neck	350 (3)	334 (3)	16 (4)		11 (4)	
Other/unknown	2612 (22)	2528 (22)	84 (21)		51 (20)	

Statistically significant variables ($p \leq 0.05$) are italicized.

SD: standard deviation; 95%CI: 95% confidence interval; MOAHLFA: Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40; OR: odds ratio.

^a Percentage over all patch-tested ($n = 12,029$).




Figure 2 Simultaneous positivity between hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrall) and Fragrance Mix II (FM II). (A) Simultaneous positivity between Lyrall and FM II among all positives. (B) Simultaneous positivity between Lyrall and FM II among positives with current relevance.

quency of age > 40 years ($p=0.024$) and lower frequency of facial involvement ($p=0.028$) (Table 4).

Discussion

The prevalence of sensitization to HICC in our study was 0.8%, lower than the 1.1% observed by Silvestre et al. in 2011–2015.¹⁶ In contrast, the frequency of FM II positivity remained stable at 3.3%.

In 1999, Frosch et al.¹⁷ recommended routine patch testing of HICC, and in 2005 defended the utility of FM II to detect more fragrance-sensitized patients,¹⁸ which led Bruze et al. to recommend inclusion of both in the European baseline series in 2008.² Since then, European studies in consecutive patients have shown a progressive decrease in HICC positivity and, to a lesser extent, FM II positivity, with current prevalences near 1% and 3%, respectively.^{5–9} This decrease relates to the 2009 recommendation of the International Fragrance Association (IFRA) to reduce HICC concentration in cosmetics¹⁹ and the European Commission's definitive ban on its use in cosmetics in 2017, effective August 23rd, 2021.²⁰

Significant variability exists in the prevalence of allergy to fragrance markers across European centers.²¹ Within the Information Network of Departments of Dermatology (IVDK), Geier et al.,^{6,22} Uter et al.,²³ Krautheim et al.,²⁴ and Schnuch et al.^{25,26} demonstrated a decline in HICC and FM II positivity from 2.6% and 5% in 1995 down to 1.1% and 3% in 2021, respectively. Similarly, though less markedly, HICC sensitization decreased significantly in the European Surveillance System on Contact Allergies (ESSCA), as shown by Uter et al.,^{7,27,28} Ahlström et al.,⁸ and Frosch et al.,²⁹ from 1.7% in 2009 down to 1.3% in 2020, with FM II remaining stable at 3.8%. In an International Contact Dermatitis Research Group (ICDRG) study from 2012 to 2016, Bruze et al.⁹ found HICC and FM II positivity frequencies of 1.6% and 3.9%, respectively. In another multicenter European cohort (2008–2011), Diepgen et al.³⁰ observed respective frequencies of 1.5% and 1.9%.

In Sweden, HICC and FM II allergy prevalence was studied by Andernord et al.,³¹ Engfeldt et al.,¹² and Isaksson et al.¹⁰

within the Swedish Contact Dermatitis Research Group (SCDRG), and by Sukakul et al.¹³ and Mowitz et al.³² in Malmö Hospital, decreasing from peaks of 1.7% and 3.4% in 2006 down to lows of 1% and 2.3% in 2020, respectively. Within SIDAPA (Società Italiana Dermatologia Allergologica Professionale Ambientale) during 2016–2021, Stingeni et al.⁵ reported respective prevalences of 1% and 2.1%. At Gentofte Hospital (Copenhagen, Denmark), Ahlström et al.⁸ observed a decrease in HICC sensitization from >2% in 2009 down to 1% in 2019. At St. John's Hospital (London, UK), Mann et al.³³ and Ung et al.³⁴ found HICC and FM II prevalences stable at 1.4% and 2.9%, respectively. At Leuven Hospital (Belgium), Nardelli et al.³⁵ observed decreasing HICC sensitization from 2007 to 2011 (mean 2.1%), while FM II remained stable (mean 6%).

In our study, allergy to HICC and FM II was clinically relevant in over half of patients, which is consistent with prior reports.^{2,8,21,30} The proportion of moderate/strong (++/+++) reactions was 58% and 56% for HICC and FM II, respectively, with low rates of irritant/doubtful reactions.

Of all HICC positives, 75% were detected by FM II, a percentage similar to that observed in cases with clinically relevant allergy to both allergens. In the literature, the proportion of FM II-positive, HICC-negative patients ranges from 10%^{34,35} to 24%,^{5,8,29} averaging 15–20% in most studies.^{9,10,12,22,24} Given these findings and the decline in HICC sensitization, several authors have advocated removal of HICC from national and European baseline series (except Stingeni et al.⁵). Indeed, the SCDRG eliminated HICC from the Swedish baseline series in 2014,¹⁰ and the ICDRG adopted the same decision for the ICDRG baseline series in 2020.¹¹ This ultimately led to exclusion of HICC from the new 2022 Spanish baseline series,⁴ moving it to the Spanish extended series—a decision supported by our findings. Considering the European Commission's ban on HICC in cosmetics,³⁶ sensitization is expected to continue declining. Nonetheless, to continue documenting this trend and given the lack of regulation of HICC use in cosmetics in non-European markets, we recommend continuing HICC patch testing within the Spanish and European extended series.

In our study, no MOAHLFA variables were associated with HICC positivity, while FM II positivity was significantly associated with age > 40 years and inversely with facial dermatitis. In the literature, female sex and age > 40 years are often associated with positivity to HICC^{5,8,10,25,29,30,37} and FM II.^{5,10,24,38} Occupational dermatitis, atopic dermatitis, and facial dermatitis have been occasionally associated with HICC^{8,37} and FM II.^{6,24,38} In our patients, the most frequent sites were hands, trunk, and face for both HICC (Table 3) and FM II (Table 4), consistent with fragrance ACD typically affecting hands, face, neck, and axillae.^{21,38,39} Interestingly, in our cohort facial dermatitis was negatively associated with FM II positivity, possibly because we only analyzed the main site without considering multiple locations. Additionally, several studies link hand involvement with FM II positivity,^{6,16,24,38} while leg involvement has been negatively associated with HICC sensitization.^{8,16,25,37,40}

In our population, occupational ACD cases were rare, at 3% for HICC and 10% for FM II. The most frequent occupations were administrative staff, service sector employees, homemakers, and healthcare workers, with no major differences by relevance (Tables 3 and 4). In general, occupational ACD due to fragrances is uncommon, mainly involving the perfume/cosmetics, domestic cleaning, esthetics/hairdressing, health care, food, metalworking, and aromatherapy industries.^{21,39} However, Montgomery et al.⁴¹ observed a gradual increase in occupational fragrance ACD cases reported in the UK during 1996–2015.

Conclusions

The prevalence of sensitization to HICC in Spain has decreased in recent years, currently standing at 0.8%. Half of the cases are clinically relevant. FM II detects 3 of every 4 patients sensitized to HICC. Our results support keeping HICC outside the Spanish baseline series and within the Spanish extended series and highlight the need to consider its transfer from the European baseline series to the European extended series.

Funding

REIDAC is promoted by the Spanish Academy of Dermatology and Venereology (AEDV, Fundación Piel Sana), which has received funding from the Spanish Agency of Medicines and Medical Devices (AEMPS) (BOE reference) and Sanofi®. The funding sources had no role in study conception, design, data collection, analysis, interpretation, manuscript preparation, review, approval, or logistical support.

Conflicts of interest

None declared.

Acknowledgments

The authors thank Dr. Francisco Javier Ortiz de Frutos (Hospital Universitario 12 de Octubre, Madrid, Spain) for providing data from his center, and Ms. Marina de Vega (AEDV Research Unit) for her support in maintaining the registry.

This work is part of the doctoral thesis of Carlos Pelayo Hernández Fernández at *Universidad de Las Palmas de Gran Canaria* (ULPGC) (Canary Islands, Spain).

References

1. Wilkinson SM, Gonçalo M, Aerts O, Badulici S, Dickel H, Gallo R, et al. The European baseline series and recommended additions: 2023. *Contact Dermatitis*. 2023;88:87–92, <http://dx.doi.org/10.1111/cod.14255>.
2. Bruze M, Andersen KE, Goossens A. Recommendation to include fragrance mix 2 and hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyr) in the European baseline patch test series. *Contact Dermatitis*. 2008;58:129–33, <http://dx.doi.org/10.1111/j.1600-0536.2007.01292.x>.
3. Arribas MP, Soro P, Silvestre JF. Dermatitis de contacto alérgica por fragancias. Parte II. *Actas Dermosifiliogr*. 2013;104:29–37, <http://dx.doi.org/10.1016/j.ad.2012.03.005>.
4. Navarro-Triviño FJ, Borrego L, Silvestre-Salvador JF, Mercader-García P, Giménez-Arnau AM, Ortiz-de Frutos FJ, et al. Actualización de la batería estándar y batería ampliada de pruebas alérgicas de contacto por el Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC). *Actas Dermosifiliogr*. 2024;115:712–21, <http://dx.doi.org/10.1016/j.ad.2024.03.024>.
5. Stingeni L, Hansel K, Corazza M, Foti C, Schena D, Fabbrocini G, et al. Contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Italy: prevalence, trend, and concordance with fragrance mix II. *Contact Dermatitis*. 2023;88:129–33, <http://dx.doi.org/10.1111/cod.14240>.
6. Geier J, Schubert S, Rieker-Schwiebacher J, Brans R, Weisshaar E, Kränke B, et al. Declining frequency of sensitization to fragrance mixes I and II: IVDK-data of the years 2012–2021. *Contact Dermatitis*. 2024;90, <http://dx.doi.org/10.1111/cod.14493>.
7. Uter W, Wilkinson SM, Aerts O, Bauer A, Borrego L, Brans R, et al. Patch test results with the European baseline series, 2019/20-Joint European results of the ESSCA and the EBS working groups of the ESCD, and the GEIDAC. *Contact Dermatitis*. 2022;87:343–55, <http://dx.doi.org/10.1111/cod.14170>.
8. Ahlström MG, Uter W, Johansen JD. Decrease of contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Europe prior to its ban and diagnostic value. *Contact Dermatitis*. 2021;84:419–22, <http://dx.doi.org/10.1111/cod.13786>.
9. Bruze M, Ale I, Andersen KE, Cannavó A, Diepgen T, Elsner P, et al. Contact allergy to fragrance mix II and hydroxyisohexyl 3-cyclohexene carboxaldehyde: a retrospective study by International Contact Dermatitis Research Group. *Dermatitis*. 2020;31:268–71, <http://dx.doi.org/10.1097/der.0000000000000545>.
10. Isaksson M, Inerot A, Lidén C, Lindberg M, Matura M, Möller H, et al. Multicentre patch testing with fragrance mix II and hydroxyisohexyl 3-cyclohexene carboxaldehyde by the Swedish Contact Dermatitis Research Group. *Contact Dermatitis*. 2014;70:187–9, <http://dx.doi.org/10.1111/cod.12156>.
11. Isaksson M, Ale I, Andersen KE, Cannavó A, Diepgen TL, Elsner P, et al. Revised baseline series of the international contact research group. *Dermatitis*. 2020;31:e5–7, <http://dx.doi.org/10.1097/der.0000000000000532>.
12. Engfeldt M, Hagvall L, Isaksson M, Matura M, Mowitz M, Ryberg K, et al. Patch testing with hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) – a multicentre study of the Swedish Contact Dermatitis Research Group. *Contact Dermatitis*. 2017;76:34–9, <http://dx.doi.org/10.1111/cod.12699>.
13. Sukakul T, Bruze M, Mowitz M, Antelmi A, Boonchai W, Dahlin J, et al. Simultaneous patch testing with fragrance markers in the baseline series and the ingredients of fragrance

- mixes: an update from southern Sweden. *Contact Dermatitis*. 2022;86:514–23, <http://dx.doi.org/10.1111/cod.14072>.
14. Hernández-Fernández CP, Mercader-García P, Silvestre Salvador JF, Sánchez Pérez J, Fernández Redondo V, Miquel Miquel FJ, et al. Candidate allergens for inclusion in the spanish standard series based on data from the Spanish Contact Dermatitis Registry [Article in English, Spanish]. *Actas Dermosifiliogr*. 2021;112:798–805, <http://dx.doi.org/10.1016/j.adengl.2021.07.013>.
 15. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing – recommendations on best practice. *Contact Dermatitis*. 2015;73:195–221, <http://dx.doi.org/10.1111/cod.12432>.
 16. Silvestre JF, Mercader P, González-Pérez R, Hervella-Garcés M, Sanz-Sánchez T, Córdoba S, et al. Sensitization to fragrances in Spain: a 5-year multicentre study (2011–2015). *Contact Dermatitis*. 2019;80:94–100, <http://dx.doi.org/10.1111/cod.13152>.
 17. Frosch PJ, Johansen JD, Menné T, Rastogi SC, Bruze M, Andersen KE, et al. Lyril is an important sensitizer in patients sensitive to fragrances. *Br J Dermatol*. 1999;141:1076–83, <http://dx.doi.org/10.1046/j.1365-2133.1999.03208.x>.
 18. Frosch PJ, Pirkner C, Rastogi SC, Andersen KE, Bruze M, Svedman C, et al. Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix. *Contact Dermatitis*. 2005;52:207–15, <http://dx.doi.org/10.1111/j.0105-1873.2005.00565.x>.
 19. Api AM, Vey M. A new IFRA standard on the fragrance ingredient, hydroxyisohexyl 3-cyclohexene carboxaldehyde. *Contact Dermatitis*. 2010;62:254–5.
 20. Commission Regulation. (EU) 2017/1410 of 2 August 2017 amending annexes II and III to regulation (EC) no 1223/2009 of the European Parliament and of the Council on cosmetic products. *Off J Eur Union*. 2017;L202:1. Available from: <https://eur-lex.europa.eu/eli/reg/2017/1410/oj> [accessed 5.5.24].
 21. De Groot AC. Fragrances: contact allergy and other adverse effects. *Dermatitis*. 2020;31, <http://dx.doi.org/10.1097/der.0000000000000463>.
 22. Geier J, Uter W, Lessmann H, Schnuch A. Fragrance mix I and II – results of breakdown tests. *Flavour Fragr J*. 2015;30:10, 1002/ffj.3247.
 23. Uter W, Gefeller O, Mahler V, Geier J. Trends and current spectrum of contact allergy in Central Europe: results of the Information Network of Departments of Dermatology (IVDK) 2007–2018. *Br J Dermatol*. 2020;183:857–65, <http://dx.doi.org/10.1111/bjd.18946>.
 24. Krauthaim A, Uter W, Frosch P, Schnuch A, Geier J. Patch testing with fragrance mix II: results of the IVDK 2005–2008. *Contact Dermatitis*. 2010;63:262–9, <http://dx.doi.org/10.1111/j.1600-0536.2010.01753.x>.
 25. Schnuch A, Uter W, Geier J, Lessmann H, Frosch PJ. Sensitization to 26 fragrances to be labelled according to current European regulation. Results of the IVDK and review of the literature. *Contact Dermatitis*. 2007;57:1–10, <http://dx.doi.org/10.1111/j.1600-0536.2007.01088.x>.
 26. Schnuch A, Geier J, Uter W. Is hydroxyisohexyl 3-cyclohexene carboxaldehyde sensitization declining in central Europe? *Contact Dermatitis*. 2012;67:47–9, <http://dx.doi.org/10.1111/j.1600-0536.2012.02126.x>.
 27. Uter W, Bauer A, Belloni Fortina A, Bircher AJ, Brans R, Buhl T, et al. Patch test results with the European baseline series and additions thereof in the ESSCA network, 2015–2018. *Contact Dermatitis*. 2021;84:109–20, <http://dx.doi.org/10.1111/cod.13704>.
 28. Uter W, Amario-Hita JC, Balato A, Ballmer-Weber B, Bauer A, Belloni Fortina A, et al. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. *J Eur Acad Dermatol Venerol*. 2017;31:1516–25, <http://dx.doi.org/10.1111/jdv.14423>.
 29. Frosch PJ, Duus Johansen J, Schuttelaar ML, Silvestre JF, Sánchez-Pérez J, Weissshaar E, et al. Patch test results with fragrance markers of the baseline series – analysis of the European Surveillance System on Contact Allergies (ESSCA) network 2009–2012. *Contact Dermatitis*. 2015;73:163–71, <http://dx.doi.org/10.1111/cod.12420>.
 30. Diepgen TL, Ofenloch R, Bruze M, Cazzaniga S, Coenraads PJ, Elsner P, et al. Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. *Br J Dermatol*. 2015;173:1411–9, <http://dx.doi.org/10.1111/bjd.14151>.
 31. Andernord D, Bruze M, Bryngelsson IL, Bråred Christensson J, Glas B, Hagvall L, et al. Contact allergy to haptens in the Swedish baseline series: results from the Swedish Patch Test Register (2010–2017). *Contact Dermatitis*. 2022;86:175–88, <http://dx.doi.org/10.1111/cod.13996>.
 32. Mowitz M, Svedman C, Zimerson E, Isaksson M, Pontén A, Bruze M. Simultaneous patch testing with fragrance mix I, fragrance mix II and their ingredients in southern Sweden between 2009 and 2015. *Contact Dermatitis*. 2017;77:280–7, <http://dx.doi.org/10.1111/cod.12834>.
 33. Mann J, McFadden JP, White JM, White IR, Banerjee P. Baseline series fragrance markers fail to predict contact allergy. *Contact Dermatitis*. 2014;70:276–81, <http://dx.doi.org/10.1111/cod.12171>.
 34. Ung CY, White JML, White IR, Banerjee P, McFadden JP. Patch testing with the European baseline series fragrance markers: a 2016 update. *Br J Dermatol*. 2018;178:776–80, <http://dx.doi.org/10.1111/bjd.15949>.
 35. Nardelli A, Carbonez A, Drieghe J, Goossens A. Results of patch testing with fragrance mix 1, fragrance mix 2, and their ingredients, and Myroxylon pereirae and colophonium, over a 21-year period. *Contact Dermatitis*. 2013;68:307–13, <http://dx.doi.org/10.1111/cod.12056>.
 36. Commission regulation (EU) 2017/1410 of 2 August 2017 amending annexes II and III to regulation (EC) no 1223/2009 of the European Parliament and of the Council on cosmetic products. *Off J Eur Union*. 2017;L202:1. Available from: <https://eur-lex.europa.eu/eli/reg/2017/1410/oj> [accessed 22.10.23].
 37. Uter W, Geier J, Schnuch A, Gefeller O. Risk factors associated with sensitization to hydroxyisohexyl 3-cyclohexene carboxaldehyde. *Contact Dermatitis*. 2013;69, <http://dx.doi.org/10.1111/cod.12069>.
 38. Uter W, Fießler C, Gefeller O, Geier J, Schnuch A. Contact sensitization to fragrance mix I and II, to Myroxylon pereirae resin and oil of tuppentine: multifactorial analysis of risk factors based on data of the IVDK network. *Flavour Fragr J*. 2015;30:255–63, <http://dx.doi.org/10.1002/ffj.3242>.
 39. Arribas MP, Soro P, Silvestre JF. Dermatitis de contacto alérgica por fragancias. Parte I. *Actas Dermosifiliogr*. 2012;103:874–9, <http://dx.doi.org/10.1016/j.ad.2012.01.015>.
 40. Sánchez-Pujol MJ, Docampo-Simón A, Mercader P, González-Pérez R, Hervella-Garcés M, Sanz-Sánchez T, et al. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. *Contact Dermatitis*. 2021;84:395–406, <http://dx.doi.org/10.1111/cod.13801>.
 41. Montgomery RL, Agius R, Wilkinson SM, Carder M. UK trends of allergic occupational skin disease attributed to fragrances 1996–2015. *Contact Dermatitis*. 2018;78:33–40, <http://dx.doi.org/10.1111/cod.12902>.